Abstract
Imatinib is a potent drug used in the treatment of all phases of chronic myeloid leukaemia (CML). It is an inhibitor of the protein kinases associated with BCR-ABL and related kinases. Various clinical trials have confirmed the efficacy of imatinib among non-transplant options. It is generally well tolerated. Reported complications include nausea, vomiting, oedema and fluid retention. We report a case of CML in which the patient developed acute pulmonary oedema following imatinib therapy. The probable cause of pulmonary oedema was cardiac morbidity due to imatinib.